CAMBRIDGE, Mass., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI - News), an innovative cancer drug discovery and development company, today announced that new data from several preclinical studies evaluating the company's innovative small molecule drug candidates -- oral Hsp90 inhibitor IPI-493 and oral Hedgehog signaling pathway inhibitor IPI-926 -- will be presented during the 20th AACR-EORTC-NCI Symposium on ``Molecular Targets and Cancer Therapeutics,'' being held in Geneva, Switzerland from October 21 through October 24, 2008.

The schedule of presentations for Infinity's drug candidates is as follows:

 Wednesday, Oct. 22, 2008: 12:00 - 2:55 p.m.
 Poster Session Title: Heat shock proteins
 Poster Presentation Title: IPI-493, a potent, orally available Hsp90
 inhibitor of the ansamycin class
 Poster number: 153
 Presenter: John Lee, Ph.D., Director, Pharmaceutical Development,
 Infinity
 Location: Poster Hall

 Wednesday, Oct. 22, 2008: 12:00 - 2:25 p.m.
 Poster Session Title: Heat shock proteins
 Poster Presentation Title: Comparison of the cellular and
 biochemical properties of ansamycin and non-ansamycin based Hsp90
 inhibitors
 Poster number: 148
 Presenter: Christian C. Fritz, Ph.D., Senior Director, Cancer Cell
 Biology, Infinity
 Location: Poster Hall

 Friday, October 24, 2008: 12:00 - 2:00 p.m.
 Poster Session Title: Signal transduction modulators
 Poster Presentation Title: Activity of IPI-926, a novel inhibitor of
 the HH pathway, in subcutaneous and orthotopically implanted
 xenograft tumors that express SHH ligand
 Poster number: 570
 Presenter: Jens Sydor, Ph.D., Director, Drug Metabolism and
 Pharmacokinetics, Infinity
 Location: Poster Hall

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company that is seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.

          Infinity Pharmaceuticals, Inc.
          Monique Allaire
          (617) 453-1105
          monique.allaire@infi.com